XML 45 R134.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Segment Information (Details) (USD $) In Millions, unless otherwise specified | 3 Months Ended | 12 Months Ended | 30 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2011 Danisco [Member] | Dec. 31, 2013 Imprelis [Member] | Dec. 31, 2012 Imprelis [Member] | Dec. 31, 2011 Imprelis [Member] | Dec. 31, 2013 Imprelis [Member] | Dec. 31, 2013 Agriculture [Member] | Dec. 31, 2012 Agriculture [Member] | Dec. 31, 2011 Agriculture [Member] | Dec. 31, 2013 Agriculture [Member] Imprelis [Member] | Dec. 31, 2012 Agriculture [Member] Imprelis [Member] | Dec. 31, 2011 Agriculture [Member] Imprelis [Member] | Dec. 31, 2013 Electronics and Communications [Member] | Dec. 31, 2013 Electronics and Communications [Member] | Dec. 31, 2012 Electronics and Communications [Member] | Dec. 31, 2013 Industrial Biosciences [Member] | Dec. 31, 2012 Industrial Biosciences [Member] | Dec. 31, 2011 Industrial Biosciences [Member] | Dec. 31, 2011 Industrial Biosciences [Member] Danisco [Member] | Dec. 31, 2013 Nutrition and Health [Member] | Dec. 31, 2012 Nutrition and Health [Member] | Dec. 31, 2011 Nutrition and Health [Member] | Dec. 31, 2011 Nutrition and Health [Member] Danisco [Member] | Dec. 31, 2013 Performance Chemicals [Member] | Dec. 31, 2012 Performance Chemicals [Member] | Dec. 31, 2013 Performance Chemicals [Member] Titanium Dioxide Antitrust Litigation [Member] | Dec. 31, 2013 Performance Materials [Member] | Dec. 31, 2013 Performance Materials [Member] | Dec. 31, 2012 Performance Materials [Member] | Dec. 31, 2011 Performance Materials [Member] | Dec. 31, 2013 Safety and Protection [Member] | Dec. 31, 2012 Safety and Protection [Member] | Dec. 31, 2013 Other [Member] | Dec. 31, 2012 Other [Member] | Dec. 31, 2011 Other [Member] | Dec. 31, 2012 Other [Member] INVISTA [Member] | Dec. 31, 2013 Employee Separation / Asset Related Charges, Net [Member] | Dec. 31, 2012 Employee Separation / Asset Related Charges, Net [Member] | Sep. 30, 2012 Employee Separation / Asset Related Charges, Net [Member] | Dec. 31, 2013 Employee Separation / Asset Related Charges, Net [Member] Performance Materials [Member] | Dec. 31, 2013 Employee Separation / Asset Related Charges, Net [Member] Performance Materials [Member] | Dec. 31, 2013 Other income, net [Member] | Dec. 31, 2012 Other income, net [Member] | Jun. 30, 2012 Other income, net [Member] | Dec. 31, 2013 Other income, net [Member] Performance Materials [Member] | Dec. 31, 2013 Other income, net [Member] Performance Materials [Member]
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pretax benefits (charges) |  | $ (556) | $ (882) | $ (411) |  |  |  |  |  | $ (351) | [1],[2] | $ (469) | [3],[4],[5] | $ (225) | [6],[7] |  |  |  |  | $ (131) | [1],[8] | $ (37) | [10],[3],[9] | $ 1 | [1] | $ (3) | [3] | $ (79) | [11],[12] |  | $ 6 | [1] | $ (49) | [3] | $ (126) | [11],[12] |  | $ (74) | [1],[13] | $ (36) | [3],[9] |  |  | $ (16) | [1] | $ (104) | [3],[9] | $ 47 | [12],[14] | $ 4 | [1] | $ (58) | [3] | $ 5 | [1] | $ (126) | [15],[3] | $ (28) | [12] |  |  |  |  |  |  |  |  |  |  |
Loss Contingency |  |  |  |  |  | (425) | (575) | (175) | (1,175) |  |  |  |  |  |  | (425) | (575) | (175) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (72) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Insurance recoveries |  |  |  |  |  | 73 |  |  |  |  |  |  |  |  |  | 73 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net restructuring adjustment | 5 | (3) |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  | (2) |  |  |  | 1 |  |  |  |  |  |  | 6 |  |  |  |  |  |  | (2) |  |  |  |  |  | (16) |  |  |  |  |  | 4 |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Benefit associated with prior year restructuring programs |  | 16 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 24 |  |  |  |  |  |  |  |  |
Charge associated with restructuring actions | (19) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (19) | (19) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (9) |  |  | (9) | (9) | (10) |  |  | (10) | (10)
Gain on sale of a business |  | 2,687 | 0 | 0 |  |  |  |  |  |  |  | 117 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 49 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 117 |  |  |
Restructuring charges |  |  | (134) | (53) |  |  |  |  |  |  |  | (11) |  |  |  |  |  |  |  |  |  | (9) |  |  |  | (3) |  | (9) |  |  |  |  | (49) |  | (14) |  |  |  |  | (3) |  |  |  |  |  | (12) |  | (2) |  |  |  | (58) |  |  |  | 11 |  | (28) |  |  |  | (66) |  |  |  |  |  |  |  |
Gain on sale of equity method investment |  | 9 | 122 | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 122 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 122 |  |
Asset impairment charges |  |  | (275) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (129) | (129) |  | (150) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (33) |  |  |  |  |  | (92) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (129) | (33) | (242) |  |  |  |  |  |  |
Charge related to litigation settlement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (137) |  |  |  |  |  |  |  |  |  |
Milestone payment associated with licensing agreement |  |  |  |  |  |  |  |  |  |  |  |  |  | (50) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition related charges |  |  |  |  | $ (182) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ (70) |  |  |  |  |  |  | $ (112) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
[1] | Included a net $(3) restructuring adjustment consisting of a $16 benefit associated with prior year restructuring programs and a $(19) charge associated with restructuring actions related to a joint venture. The majority of the $16 net reduction recorded in Employee separation/asset related charges, net was due to the achievement of work force reductions through non-severance programs associated with the 2012 restructuring program. The charge of $(19) included $(9) recorded in Employee separation/asset related charges, net and $(10) recorded in Other income, net and was the result of restructuring actions related to a joint venture within the Performance Materials segment. Pre-tax amounts by segment were: Agriculture - $1, Electronics & Communications - $(2), Industrial Biosciences - $1, Nutrition & Health - $6, Performance Chemicals - $(2), Performance Materials - $(16), Safety & Protection - $4; and Other - $5. See Note 3 for additional information.
[2] | Included charges of $(425), offset by $73 of insurance recoveries, recorded in Other operating charges associated with the company's process to fairly resolve claims related to the use of Imprelis®. See Note 16 for additional information.
[3] | Included a $(134) restructuring charge recorded in Employee separation/asset related charges, net primarily as a result of the company's plan to eliminate corporate costs previously allocated to Performance Coatings and cost-cutting actions to improve competitiveness, partially offset by a reversal of prior year restructuring accruals. Charges by segment were: Agriculture - $(11); Electronics & Communications - $(9); Industrial Biosciences - $(3); Nutrition & Health - $(49); Performance Chemicals - $(3); Performance Materials - $(12); Safety & Protection - $(58); and Other - $11. See Note 3 for additional information.
[4] | Included a $117 gain recorded in Other income, net associated with the sale of a business.
[5] | Included a $(575) charge recorded in Other operating charges associated with the company's process to fairly resolve claims related to the use of Imprelis®. See Note 16 for additional information.
[6] | Included a $(175) charge recorded in Other operating charges associated with the company's process to fairly resolve claims associated with the use of Imprelis®. See Note 16 for additional information.
[7] | Included a $(50) charge recorded in Research and development expense in connection with a milestone payment associated with a Pioneer licensing agreement. Since this milestone was reached before regulatory approval was secured by Pioneer, it was charged to Research and development expense.
[8] | ncluded a $(129) impairment charge recorded in Employee separation/asset related charges, net related to an asset grouping within the Electronics & Communications segment. See Note 3 for additional information.
[9] | Included a $(275) impairment charge recorded in Employee separation/asset related charges, net related to asset groupings, which impacted the segments as follows: Electronics & Communications - $(150); Performance Chemicals - $(33); and Performance Materials - $(92). See Note 3 for additional information.
[10] | Included a $122 gain recorded in Other income, net associated with the sale of an equity method investment.
[11] | Included a $(182) charge for transaction related costs and the fair value step-up of inventories that were acquired as part of the Danisco transaction, which impacted the segments as follows: Industrial Biosciences - $(70) and Nutrition & Health - $(112).
[12] | Included a $(53) restructuring charge primarily related to severance and related benefit costs associated with the Danisco acquisition impacting the segments as follows: Industrial Biosciences - $(9); Nutrition & Health - $(14); Performance Materials - $(2); and Other - $(28).
[13] | Included a $(72) charge recorded in Other operating charges related to the titanium dioxide antitrust litigation. See Note 16 for additional information.
[14] | Included a $49 benefit recorded in Other income, net associated with the sale of a business.
[15] | Included a $(137) charge in Other operating charges primarily related to the company's settlement of litigation with INVISTA.

X
- Definition Acquisition related charges including transaction related costs and the fair value step-up of inventories that were acquired and restructuring costs. + References No definition available. + Details
Name: | dd_AcquisitionRelatedCharges
Namespace Prefix: | dd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Net charge resulting from restructuring actions related to a joint venture within the Performance Materials segment. + References No definition available. + Details
Name: | dd_ChargeAssociatedWithRestructuringActions
Namespace Prefix: | dd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Insurance recoveries for litigation. + References No definition available. + Details
Name: | dd_InsuranceRecoveriesforLitigation
Namespace Prefix: | dd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment associated with a licensing agreement. + References No definition available. + Details
Name: | dd_MilestonePaymentAssociatedWithLicensingAgreement
Namespace Prefix: | dd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Net restructuring adjustment consisting of a benefit associated with prior year restructuring programs and a charge associated with restructuring actions related to a joint venture. + References No definition available. + Details
Name: | dd_NetRestructuringAdjustment
Namespace Prefix: | dd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Segment Reporting Information Other Benefit (Charge) + References No definition available. + Details
Name: | dd_SegmentReportingInformationOtherBenefitCharge
Namespace Prefix: | dd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of gain (loss) on sale or disposal of an equity method investment. + References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Gain (loss) from sale or disposal of an organization or integrated set of activities (for example, but not limited to, a partnership or corporation) engaged in providing a product or service in a commercial, industrial, or professional environment. + References No definition available. + Details
Name: | us-gaap_GainLossOnSaleOfBusiness
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 + Details
Name: | us-gaap_GainLossRelatedToLitigationSettlement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyLossInPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4(b)) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section P -Subsection 3, 4 + Details
Name: | us-gaap_RestructuringAndRelatedCostIncurredCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of any reversal and other adjustment made during the period to the amount of a previously accrued liability for a specified type of restructuring cost, excluding adjustments for costs incurred during the period, costs settled during the period, and foreign currency translation adjustments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4(b)) -URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section P -Subsection 3, 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 40 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6394291&loc=d3e17658-110867 + Details
Name: | us-gaap_RestructuringReserveAccrualAdjustment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration